To Patients

Therapeutic Approach

Reducing Inflammation

EMFLAZA® (deflazacort) is a corticosteroid that demonstrates anti-inflammatory and immunosuppressant effects.


EMFLAZA® is indicated for the treatment of Duchenne muscular dystrophy in patients 2 years of age and older (download EMFLAZA® label & prescribing information).

For additional resources regarding eligibility and access, view PPMD’s Insurance Access & Coverage Roadmap.


This program is sponsored by PTC Therapeutics.

Media Library

JUNE 2021

PTC Therapeutics Presents at the PPMD 2021 Virtual Annual Conference

Pre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library
JUNE 2019

PTC Therapeutics Presents at the PPMD 2019 Annual Conference

OCT 2018

Webinar: An Update on Corticosteroids

PPMD and Dr. John Brandsema hosted a webinar on October 24, 2018 to discuss the current guidelines for steroid use in Duchenne muscular dystrophy, emerging data, and best practices.

Join Our Mailing List